The world of healthcare investing is about to see the return of two of their titans working together. Previously a team at Merlin BioMed Group, Jacob Gottlieb and Stuart Weisbrod are once again teaming up together but this time they have formed their own new company, Altium Capital. It’s been almost 20 years since the 2 have shared the same office but since then they have both achieved a lot when they had gone their own investing ways.
The former colleagues made a lot of successful investment decisions when they worked together before and after. The financial world will see some new innovations and changes to how healthcare investments are done. Jacob Gottlieb is still busy winding down his duties as the chief executive officer for his former business, Visium Asset Management, but he is still already involved in his new hedge fund.
Altium will be making investments in many different healthcare related opportunities as Jacob Gottlieb and Weisbrod have done before and are interested in companies that will potentially innovate their industries. One of their first investments is lined up to do just that by creating a new way for diabetes patients to take their insulin. Currently, Jacob Gottlieb and Weisbrod’s Altium has purchased a stake in Oramed at 5.61%.
Oramed is based in Jerusalem and has created an innovative product that allows insulin to be taken orally. Prior to Oramed’s capsule technology, it was impossible for patients to take their medication in this fashion and they were forced to treat their illness through painful injections or insulin pumps. Other companies have tried to create a pill form of insulin before but they were not able to do it successfully. This is because the insulin did not stay viable and lost its effectiveness when it reached the digestive tract of the patient.
One of the markets that Oramed is showing the most potential is China. They were able to reach a licensing deal worth $50 million for the medication to be used in Hong Kong, Macau, and China. Prior to this, they received an investment from a company based in China for $52 million.
Oramed is still waiting to get their medication approved by the Food and Drug Administration in the United States but the prospects look promising. The medication is in late-stage clinical trials in the United States and is expected to make permanent changes in how diabetes is treated. The new medication supported by Jacob Gottlieb’s Altium is gaining attention internationally as it progresses.
Find out more about Jacob Gottlieb: https://www.linkedin.com/in/jacob-gottlieb/